Literature DB >> 21723634

Accessing radiation response using hypoxia PET imaging and oxygen sensitive electrodes: a preclinical study.

Lise Saksø Mortensen1, Morten Busk, Marianne Nordsmark, Steen Jakobsen, Jørn Theil, Jens Overgaard, Michael R Horsman.   

Abstract

PURPOSE: Tumor hypoxia is a known cause of resistance to radiotherapy. The aim of this study was to investigate the prognostic value of hypoxia measured by (18)F-fluoroazomycin arabinoside ((18)F-FAZA) PET or the Eppendorf oxygen electrode in a pre-clinical tumor model. MATERIAL/
METHODS: Pretreatment (18)F-FAZA PET scans and blood sampling was conducted in 92 Female CDF1 mice with subcutaneous C3H mammary carcinomas grown in the right foot. Similarly, oxygenation status of 80 equivalent tumors was assessed using an invasive oxygen sensitive electrode. Tumors were then irradiated with a single dose of 55 Gy and local tumor control up to 90 days after the treatment was determined.
RESULTS: A significant difference in local tumor control between "more hypoxic" or "less hypoxic" groups separated either by a median (18)F-FAZA PET determined tumor-to-blood ratio (P=0.007; hazard ratio, HR=0.21 [95% CI: 0.06-0.74]), or the fraction of oxygen partial pressure (pO(2)) values ≤2.5 mmHg (P=0.018; HR=0.31 [95% CI: 0.11-0.87]), was found. Both assays showed that the more hypoxic tumors had significantly lower tumor control.
CONCLUSION: (18)F-FAZA PET analysis showed that pre treatment tumor hypoxia was prognostic of radiation response. Similar results were obtained when oxygenation status was assessed by the Eppendorf pO(2) Histograph. The results of this study support the role of (18)F-FAZA as a non-invasive prognostic marker for tumor hypoxia.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21723634     DOI: 10.1016/j.radonc.2011.06.034

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  14 in total

Review 1.  Imaging radiation response in tumor and normal tissue.

Authors:  Marjan Rafat; Rehan Ali; Edward E Graves
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-06-15

2.  Quantification of Tumor Hypoxic Fractions Using Positron Emission Tomography with [18F]Fluoromisonidazole ([18F]FMISO) Kinetic Analysis and Invasive Oxygen Measurements.

Authors:  Olivia J Kelada; Sara Rockwell; Ming-Qiang Zheng; Yiyun Huang; Yanfeng Liu; Carmen J Booth; Roy H Decker; Uwe Oelfke; Richard E Carson; David J Carlson
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

Review 3.  A review of flux considerations for in vivo neurochemical measurements.

Authors:  David W Paul; Julie A Stenken
Journal:  Analyst       Date:  2015-06-07       Impact factor: 4.616

Review 4.  PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence.

Authors:  Egesta Lopci; Ilaria Grassi; Arturo Chiti; Cristina Nanni; Gianfranco Cicoria; Luca Toschi; Cristina Fonti; Filippo Lodi; Sandro Mattioli; Stefano Fanti
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-06-07

Review 5.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

6.  PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice.

Authors:  M Busk; L S Mortensen; M Nordsmark; J Overgaard; S Jakobsen; K V Hansen; J Theil; J F Kallehauge; F P D'Andrea; T Steiniche; M R Horsman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-18       Impact factor: 9.236

Review 7.  The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities.

Authors:  Joseph C Walsh; Artem Lebedev; Edward Aten; Kathleen Madsen; Liane Marciano; Hartmuth C Kolb
Journal:  Antioxid Redox Signal       Date:  2014-05-09       Impact factor: 8.401

8.  Significant impact of different oxygen breathing conditions on noninvasive in vivo tumor-hypoxia imaging using [¹⁸F]-fluoro-azomycinarabino-furanoside ([¹⁸F]FAZA).

Authors:  Florian C Maier; Manfred Kneilling; Gerald Reischl; Funda Cay; Daniel Bukala; Andreas Schmid; Martin S Judenhofer; Martin Röcken; Hans-Jürgen Machulla; Bernd J Pichler
Journal:  Radiat Oncol       Date:  2011-11-25       Impact factor: 3.481

9.  18F-EF5 PET Is Predictive of Response to Fractionated Radiotherapy in Preclinical Tumor Models.

Authors:  Rehan Ali; Sandeep Apte; Marta Vilalta; Murugesan Subbarayan; Zheng Miao; Frederick T Chin; Edward E Graves
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

10.  Longitudinal tumor hypoxia imaging with [(18)F]FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity.

Authors:  Jinzi Zheng; Stephan G Klinz; Raquel De Souza; Jonathan Fitzgerald; David A Jaffray
Journal:  EJNMMI Res       Date:  2015-10-19       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.